-
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 30-34 weeks' gestation.
Tsiakkas A, Saiid Y, Wright A, Wright D, Nicolaides KH.
Am J Obstet Gynecol 2016;215:87.e1-87.e17. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM, Wright D, Casanova C, Campanero M, Nicolaides KH.
Am J Obstet Gynecol 2016;214:619.e1-619.e17. pdf -
Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:584-90. pdf -
Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
Fadigas C, Peeva G, Mendez O, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:191-7. pdf -
Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
Bakalis S, Peeva G, Gonzalez R, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:446-51. pdf -
Prediction of small-for-gestational-age neonates: maternal biochemical markers at 30-34 weeks.
Bakalis S, Gallo DM, Mendez O, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015:46:208-15. pdf -
Prediction of small for gestational age neonates: Screening by maternal serum biochemical markers at 19-24 weeks.
Lesmes C, Gallo DM, Gonzalez R, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:341-9. pdf -
Prediction of small for gestational age neonates: screening by biophysical and biochemical markers at 19-24 weeks.
Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;46:437-45. pdf -
Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation.
Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;35:240-8. pdf -
Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation.
Garcia-Tizon Larroca S, Tayyar A, Poon LC, Wright D, Nicolaides KH.
Fetal Diagn Ther 2014;36:9-17. pdf -
Maternal serum vitamin D levels at 11-13 weeks of gestation in preeclampsia.
Yu CK, Ertl R, Skyfta E, Akolekar R, Nicolaides KH.
Hum Hypertens 2013;27:115-8 . pdf -
Maternal serum vitamin D at 11-13 weeks in pregnancies delivering small for gestational age neonates.
Ertl R, Yu CK, Samaha R, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2012;31:103-8. -
Maternal serum 25-hydroxyvitamin D levels at 11(+0) -13(+6) weeks in pregnant women with diabetes mellitus and in those with macrosomic neonates.
Savvidou M, Akolekar R, Samaha R, Masconi A, Nicolaides Kh.
BJOG 2011;118:951-5. -
First-trimester circulating 25-hydroxyvitamin d levels and development of gestational diabetes mellitus.
Makgoba M, Nelson SM, Savvidou M, Messow CM, Nicolaides K, Sattar N.
Diabetes Care 2011;34:1091-3.